Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients

Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, outlines the results of the Checkmate 142 study looking at Yervoy (ipilimumab) and Opdivo (nivolumab) in metastatic colorectal cancer (mCRC) patients